See more : Mitsubishi Heavy Industries, Ltd. (7011.T) Income Statement Analysis – Financial Results
Complete financial analysis of Absci Corporation (ABSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Absci Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- The Allstate Corporation (ALL-PH) Income Statement Analysis – Financial Results
- Chennai Ferrous Industries Limited (CHENFERRO.BO) Income Statement Analysis – Financial Results
- Oasis Midstream Partners LP (OMP) Income Statement Analysis – Financial Results
- Selkirk Group Plc (SELK.L) Income Statement Analysis – Financial Results
- Tradeweb Markets Inc. (US8926721064.SG) Income Statement Analysis – Financial Results
Absci Corporation (ABSI)
About Absci Corporation
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 5.72M | 5.75M | 4.78M | 4.78M | 2.06M |
| Cost of Revenue | 47.57M | 13.04M | 6.65M | 11.45M | 4.31M |
| Gross Profit | -41.85M | -7.29M | -1.87M | -6.67M | -2.25M |
| Gross Profit Ratio | -731.88% | -126.85% | -39.15% | -139.50% | -109.27% |
| Research & Development | 48.07M | 58.91M | 44.59M | 11.45M | 4.31M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 37.83M | 40.55M | 28.78M | 5.50M | 3.52M |
| Other Expenses | 35.33M | 13.04M | 6.65M | 1.13M | 491.00K |
| Operating Expenses | 121.23M | 112.50M | 80.02M | 18.08M | 8.33M |
| Cost & Expenses | 121.23M | 112.50M | 80.02M | 18.08M | 8.33M |
| Interest Income | 0.00 | 972.00K | 3.43M | 634.00K | 268.00K |
| Interest Expense | 1.01M | 972.00K | 3.43M | 634.00K | 268.00K |
| Depreciation & Amortization | 14.00M | 13.04M | 6.65M | 1.13M | 491.00K |
| EBITDA | -95.46M | -91.36M | -99.77M | -12.59M | -5.83M |
| EBITDA Ratio | -1,669.41% | -1,589.63% | -2,086.43% | -263.35% | -282.77% |
| Operating Income | -115.52M | -106.75M | -75.24M | -13.30M | -6.27M |
| Operating Income Ratio | -2,020.20% | -1,857.49% | -1,573.36% | -278.26% | -304.13% |
| Total Other Income/Expenses | 5.05M | 1.39M | -34.62M | -1.05M | -319.00K |
| Income Before Tax | -110.47M | -105.37M | -109.86M | -14.35M | -6.58M |
| Income Before Tax Ratio | -1,931.90% | -1,833.39% | -2,297.34% | -300.27% | -319.61% |
| Income Tax Expense | 100.00K | -461.00K | -8.90M | 216.00K | 217.00K |
| Net Income | -110.57M | -104.90M | -100.96M | -14.57M | -6.80M |
| Net Income Ratio | -1,933.65% | -1,825.37% | -2,111.25% | -304.79% | -330.15% |
| EPS | -1.20 | -1.15 | -1.09 | -0.16 | -0.07 |
| EPS Diluted | -1.20 | -1.15 | -1.09 | -0.16 | -0.07 |
| Weighted Avg Shares Out | 92.03M | 90.85M | 92.65M | 92.25M | 92.25M |
| Weighted Avg Shares Out (Dil) | 92.03M | 90.85M | 92.65M | 92.25M | 92.25M |
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
Absci Corporation (ABSI) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.33 per share a year ago.
Absci Takes Its Generative AI Antibody Design Platform To Europe
Generative AI technology, like ChatGPT, is disrupting many industries including biopharma. For example, Absci is using AI to design & validate de novo antibodies.
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.
Here's Why Absci Corp Shares Are Falling
Absci Corp (NASDAQ: ABSI) shares are trading lower by 9.2% at $6.79 after the company reported fourth-quarter earnings results. Absci reported quarterly losses of 28 cents per share.
2seventy bio Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2021. “We launched 2seventy bio at the end of 2021 with...
Absci to Present at Global AI Conference NVIDIA GTC
VANCOUVER, Wash., March 16, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a drug and target discovery company harnessing deep learning, AI and synthetic biology to expand the therapeutic potential of proteins, today announced that Absci Lead AI Scientist Joshua...
Is a Surprise Coming for Absci (ABSI) This Earnings Season?
Absci (ABSI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually...
2seventy bio Announces Key Management Appointments
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (NASDAQ: TSVT) announced that Steven Bernstein, M.D. will join the company effective today and assume the role of chief medical officer (CMO). Also announced today, Susan Abu-Absi, Ph.D. has been appointed chief technology & manufacturing...
Source: https://incomestatements.info
Category: Stock Reports